Sage Journals: Discover world-class research

Abstract

Premenstrual dysphoric disorder (PMDD) is comprised of a cluster of affective, behavioral and somatic symptoms recurring monthly during the luteal phase of the menstrual cycle. The disorder affects 3–8% of menstruating women and represents the more severe and disabling end of the spectrum of premenstrual disorders, which includes premenstrual syndrome and premenstrual aggravation of underlying affective disorder. Rigorous and specific diagnostic criteria for PMDD were specified in the Diagnostic and Statistical Manual of Mental Disorders IV (1994) and reaffirmed in the Diagnostic and Statistical Manual of Mental Disorders V (2013) and, consequently, there has been a marked increase in well-designed, placebo-controlled studies evaluating treatment modalities. Although the exact pathogenesis of PMDD is still elusive, treatment of PMDD and severe premenstrual syndrome has centered on neuromodulation via serotonin reuptake inhibitor antidepressants, and ovulation suppression utilizing various contraceptive and hormonal preparations. Unlike the approach to the treatment of depression, serotonergic antidepressants need not be given daily, but can be effective when used cyclically, only in the luteal phase or even limited to the duration of the monthly symptoms. Less, well-substantiated alternative treatments, such as calcium supplementation, agnus castus (chasteberry), Hypericum perforatum (St John's wort) and cognitive/behavioral/relaxation therapies, may be useful adjuncts in the treatment of PMDD. This review provides an overview of current information on the treatment of PMDD.

Keywords

PMDD PMS pharmacologic therapy premenstrual dysphoric disorder premenstrual syndrome

Definition of premenstrual dysphoric disorder

Premenstrual complaints of a physical and emotional nature are common, affecting up to 90% of ovulatory women. Symptom onset can occur up to 2 weeks before menses and resolve soon after the onset of the menstrual period. A symptom-free interval after the end of the menstrual flow and before ovulation is required for the symptoms to be consistent with a premenstrual disorder (PMD) [1]. The most debilitating and severe symptoms are emotional and behavioral, and include irritability, depression, mood lability, anxiety, feelings of ‘loss of control’, difficulty concentrating and fatigue. Physical symptoms often include abdominal bloating, breast tenderness, headache and generalized aches [2,3].

The specific diagnosis of premenstrual dysphoric disorder (PMDD) was introduced by the American Psychiatric Association in Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (1994) [4], but remained in the appendix as it was believed that additional research was needed to confirm the distinctive-ness of the diagnosis from other disorders [5]. Most recently in the newly published DSM-V (2013), PMDD is no longer in the appendix, but is a full diagnostic category [6]. The diagnosis of PMDD requires at least five of the 11 specific premenstrual symptoms including one of the core mood symptoms (marked depression, anxiety or tension, mood swings or persistent anger and irritability; Box 1). Dysfunction in the home, social and occupational spheres related to the symptoms must be present for most menstrual cycles over the past year, and symptoms must be documented prospectively for at least two menstrual cycles to confirm the premenstrual timing of the symptoms and the postmenstrual symptom-free-interval [6]. The move to include PMDD as a full diagnostic category under mood disorders came after careful review of diagnostic stability in clinical and epidemiologic cohorts. The most potent predictive validator of PMDD as a distinct disorder is the preferential response to serotonergic antidepressants and to certain hormonal treatments [5].

The American College of Obstetricians and Gynecologists [7], the Royal College of Obstetricians and Gynecologists [8], and most recently the International Society for the Study of Premenstrual Disorders (ISPMD) [1], have published diagnostic criteria for PMDs. Specifically, the consensus of the members of the ISPMD was that both premenstrual syndrome (PMS) and PMDD fall under the umbrella of a ‘core PMD’. To be classified as a core PMD, the symptoms need not be specific in type or number, but must be severe enough to cause impairment, and must occur during ovulatory cycles and be absent between the end of menses and ovulation. The ISPMD identified variants of PMD that fall outside of the strict definitions of PMS and PMDD, but that may respond to similar treatment modalities [1]. These variants include: cyclic symptoms occurring without menstruation, such as after hysterectomy (with ovarian retention) or endometrial ablation; premenstrual exacerbation of an underlying psychological or somatic diagnosis; symptoms resulting from exogenous progestagen administration; or symptoms due to nonovulatory fluctuations in ovarian activity.

Box 1.

Diagnostic criteria for premenstrual dysphoric disorder.

Five (or more) of the following symptoms occurred during the week before menses and remitted a few days after the onset of menses. At least one of the symptoms being either 1, 2, 3 or 4:

Marked lability (e.g., mood swings, suddenly feeling sad or tearful, or increased sensitivity to rejection)

Marked irritability or anger

Markedly depressed mood

Marked anxiety and tension

Decreased interest in usual activities

Difficulty in concentration

Lethargy and marked lack of energy

Marked change in appetite (e.g., overeating or specific food cravings)

Hypersomnia or insomnia

Feeling overwhelmed or out of control

Physical symptoms (e.g., breast tenderness or swelling, joint or muscle pain, a sensation of ‘bloating’ and weight gain)

The symptoms interfere with work, school, usual social activities or relationships with others

The symptoms are not an exacerbation of the symptoms of another disorder (e.g., major depressive disorder, panic disorder, dysthymic disorder or a personality disorder)

Criteria A, B and C should be confirmed by prospective daily ratings during at least two consecutive cycles

The symptoms are not due to the direct physiologic effects of drugs of abuse, medications or an underlying medical disorder

Adapted with permission from [6].

Epidemiology

A total of 20–30% of women may be affected by moderate-to-severe symptoms that meet criteria for PMS, and 3–8% will fulfill the strict criteria for PMDD [9]. The prevalence of PMDD is not specific to geography, with similar reported estimates between 3–8% in countries such as India, Iceland, Germany and the USA [10]. Surprisingly, one study found that up to 18% of women lacked only one of the requisite symptoms for a PMDD classification, indicating that many women are ‘near threshold’ for the diagnosis [11]. It has been estimated that 20% of reproductive-aged women have debilitating symptoms causing significant impairment that warrant treatment [12] . Recent cross-sectional surveys undertaken in Europe, Latin America and Asia found that, of 7226 women studied, the most prevalent premenstrual symptoms were of the physical domain - abdominal bloating, irritability, mastalgia and joint/muscle/back pains [10]. However, this survey did not assess the prevalence of PMDD specifically. Certain sociodemographic factors were associated with decreased severity of symptoms such as age extremes (young and old), higher parity and nonsmoking. Although some countries, such as the UK, Brazil, Japan, Korea and Austrialia, were characterized by greater PMS severity, all the other countries did not differ from one another. The global database indicates that premenstrual and menstrual symptoms are not influenced by country or culture [10].

Women with PMDD manifest a 50–78% lifetime incidence of psychiatric disorders such as dysthymic disorder, major depressive disorder, seasonal affective disorder and generalized anxiety disorder [13 –15]. The prevalence of the co-occurrence of PMDD with bipolar disorder or schizophrenia has not been established owing to the limited number of prospective studies. However, there are case reports and retrospective studies of women with schizophrenia, which suggests there may be an association [16]. Retrospective studies have noted increased prevalence of severe PMS in women with bipolar disorder [16]. Although PMDD and schizophrenia can co-occur, the premenstrual phase is not specifically a time of vulnerability for psychosis [16]. Case reports suggest that women can manifest premenstrual psychosis [17].

Burden of disease

PMS can have a negative impact on daily functioning at home, in the workplace and in social interactions [18 –20]. Specifically, women with PMDD were found to have substantial impairment of productivity in the workplace and a higher rate of absenteeism [21,22]. They were also more likely to visit their physicians and incur higher healthcare costs [23,24]. The adverse effect of PMDD on health-related quality of life was found to be greater than chronic back pain, and comparable to debilitating conditions, such as osteoarthritis and rheumatoid arthritis [25]. The degree of impairment of interpersonal relationships during the late-luteal phase for women with PMDD was comparable to the levels experienced by women with chronic clinical depression [9]. Most concerning is that women suffering from PMDD were significantly more likely to report suicidal ideation than their counterparts without PMS [26,27]. Women menstruate up to 400–500 times over the course of their reproductive years, rendering the burden of illness for PMDD similar to that of dysthymic and depressive disorders [28].

Diagnosis

Crucial to the accurate diagnosis of PMDD is a complete history and accurate documentation of the timing of the symptoms in relation to the menstrual cycle.

The diagnosis of a PMD requires a consistent pattern of psychological, physical and/or behavioral symptoms that begin during the luteal phase, and that resolve completely during menses. The symptoms must be of moderate-to-severe intensity and result in some interference with, or impairment of, daily activities or functioning. Daily prospective charting for two menstrual cycles to accurately confirm the timing of the symptoms is required by all published criteria [1,6]. Retrospective recall of symptoms has low specificity and is considered unreliable [29]. Critical for the diagnosis is a symptom-free week early in the follicular phase, which differentiates a PMD from a psychiatric disorder (which lacks this regularly timed symptom-free interval) [30]. Charting of symptoms also allows clinicians to differentiate between mild PMS and moderate-to-severe PMS and PMDD, and can help exclude exacerbations of underlying psychological conditions [28] . There are several psychometric measures used clinically and in research studies. The Daily Record of Severity of Problems is a validated prospective daily rating scale, which allows women to track 11 symptoms across their menstrual cycle [31]. One retrospective tool, the Premenstrual Symptoms Screening Tool (PSST) has recently been validated as an excellent screener to determine who may benefit from more involved prospective daily recording of symptoms [32]. In practice, a simple rating scale can be devised by asking the patient to list (on a piece of paper or in a computer file) her five or more most significant symptoms vertically and the days of the month (1–31) across the top horizontally, and to circle the days of her menstrual flow. She can then rate the symptoms nightly on a scale from 0 ('none') to 3 ('severe') with 1 being ‘mild’ and 2 being ‘moderate’. Impairment of activities can be denoted by an asterix next to the disabling symptom.

A thorough medical history and physical examination can help to rule out any underlying medical disorders. Attention should also be given to ruling out medical conditions subject to premenstrual flare such as hypothyroidism, anemia, dysmenorrhea, irritable bowel syndrome, interstitial cystitis, endometriosis, chronic pelvic pain, chronic fatigue syndrome, connective tissue and rheumatologic disorders [33].

An understanding of the patient's social history is pertinent, with attention given to any incidents of domestic violence, physical or emotional trauma, or substance abuse, owing to the close association between PMS/PMDD with such a history [34,35]. Screening for psychiatric illnesses, such as dysthymic disorder, major depressive disorder, seasonal affective disorder and generalized anxiety disorder, should be undertaken if indicated, particularly if the daily ratings reveal follicular-phase symptoms suggesting that the PMS may be an exacerbation of an underlying disorder or in the presence of suicidal or homicidal ideation. Family history, past history of major depression and postpartum depression are risk factors for the development of PMDD and affective disorders [13 –15].

Many women are not pleased with the request to delay treatment until after the completion of daily ratings, but will often comply when told that accurate diagnosis is important and not possible without the daily ratings. They should also be told that treatment may differ in nature or duration depending on the diagnosis. Recording symptoms and clarifying the relationship with the premenstrual phase can also give the patient a sense of control and help her to educate family members about the neuroendocrine nature of the disorder and, therefore, the patient may find the completion of the daily ratings to be therapeutic. Lifestyle changes that may be helpful to initiate during this time are addressed below and include dietary changes, exercise and relaxation strategies.

Pathophysiology

Fluctuations in ovarian sex steroids

The exact pathophysiology of PMDD is still unknown. The specific timing of the symptoms, triggered by ovulation, peaking in the late-luteal phase and resolving during menses, indicates that the fluctuations in gonadal sex steroids, particularly progesterone, are involved in the pathogenesis of PMDD. Symptoms of PMDD are absent premenarchally and, in nonovulatory cycles [36], disappear in ovariectomized women and those subjected to suppression of ovulation [37 –39], and abate with menopause [40 –42]. Women with premenstrual disorders also appear to have a differential sensitivity to exposure and/or withdrawal of circulating ovarian sex steroids. Schmidt et al. found that women with PMS who had undergone ‘medical menopause’ via administration of a gonadotropin releasing hormone (GnRH) agonist experienced relief of symptoms, but then developed negative symptoms after exposure to physiologic doses of exogenous estradiol or progesterone. Women without PMS had no negative side effects after receiving these hormones [43].

Allopregnanolone, pregnanolone & GABA

Investigators have also hypothesized that the metabolites of progesterone, which have been found to have neuroactive properties, might be implicated in the pathogenesis of PMD. Of particular interest are the neuroactive steroids, allopregnanolone or ALLO (3α-hydroxy-5α-pregnan-20-one) and pregnanolone (3α-hydroxy-5β-pregnane-20-one), which are metabolites of progesterone produced in the ovary, adrenal glands and brain [44]. Both ALLO and pregnanolone are positive modulators of the GABA neurotransmitter system in the brain. GABA is the main inhibitory neurotransmitter in the mammalian brain and is crucial for regulation of anxiety, vigilance, alertness, stress and seizures [45]. Some, but not all, studies have shown decreased peripheral ALLO during the luteal phase of affected women [46 –48]. Given that this hormone readily crosses the blood–brain barrier, lower ALLO concentrations might result in decreased GABA-mediated neural inhibition [49]. Most clinical evidence and findings from animal models of progesterone withdrawal point to reduced functional sensitivity of the GABA receptor during the luteal phase in women with PMD [50,51]. It has been demonstrated in rats that exposure to progesterone changes the configuration of the GABA receptor, rendering it temporarily insensitive to further modulation by the neurosteroid metabolites of progesterone [52,53].

Serotonin

Important for understanding pharmacologic treatment of PMDD is the role of serotonin (5-HT, 5-hydroxytryptamine) in the pathophysiology of the disorder. Women with PMS/PMDD have been found to have abnormalities in their serotonergic transmission, with a lower density of serotonin transporter receptors [54]. PMDD symptoms can be provoked in susceptible women if tryptophan, the precursor of serotonin, is depleted [55], or if a serotonin antagonist is administered [56]. Peripheral serotonergic function has been shown to be altered during the luteal phase in women with PMS, with decreased platelet uptake of serotonin [57], decreased whole-blood serotonin [58] and decreased platelet monoamine oxidase activity [59]. Peripheral measures of serotonergic functioning are reasonable, since the platelet has similar uptake properties to the serotonergic neuron in the brain. However, a direct role for serotonin in PMDD was suggested by a PET study, which found that daily mood ratings of symptomatic women significantly correlated with changes in brain trapping of ¹¹C-labeled 5-hydroxytryptophan in various brain regions across the menstrual cycle [60].

Cortical reactivity & startle response

Several studies have demonstrated that women with PMDD have altered cortical activity or physiologic arousal relative to healthy comparison patients. Smith et al. demonstrated that with magnetic stimulation, symptomatic women do not experience the normal increase in neuronal inhibition in the luteal phase, a time when progesterone and ALLO levels are elevated [61] . Furthermore, investigators have evaluated the acoustic startle response in women with PMDD. Acoustic startle response is a withdrawal reflex to sudden or noxious auditory stimuli, and a measure of emotional processing of appetitive and aversive stimuli. Women with PMDD have demonstrated a greatly accentuated baseline startle response during the symptomatic luteal phase compared with normal controls [62 –64]. The etiology of the increase in this startle response has yet to be elucidated.

Brian neurocircuitry

Recent studies have indicated that the brain structure and function are altered in women with PMDD [65 –67]. Ovarian steroids have been found to modulate activity in brain regions relevant to the symptoms of PMDD, including the prefrontal cortex, reward systems and stress neurocircuitry [68]. Baller et al. found that when compared with healthy controls, patients with PMDD displayed abnormal patterns of brain activation during working memory on both PET and functional MRI studies. Specifically, these differences were noted in the dorsolateral prefrontal cortex, which is crucial to the cognitive, emotional and social functions affected in PMDD [68]. The study controlled for hormonal fluctuations with GnRH suppression, and found that there were persistent differences between those with PMDD and asymptomatic women, suggesting a ‘trait-like’ predisposition to PMDD. Rapkin et al., using PET, found that women with PMDD, but not asymptomatic controls, had significantly increased cerebellar activity from the follicular phase to the late-luteal phase. These changes were paralleled with a worsening mood, and further support data implicating the cerebellum in a wide range of behaviors involving pain and executive functions [66]. The cerebellum is rich in GABA receptors and increased activity may also be a reflection of a deficiency of GABAergic inhibition [66].

Pharmacologic treatment of PMDD

Pharmacologic therapy is usually indicated for women with severe PMDD. Lifestyle modifications, such as increasing aerobic exercise and dietary changes consisting of increased calcium intake, reduced caffeine intake and increased carbohydrate intake (premenstrually), are helpful for PMS, but usually fail to relieve symptoms of PMDD [69]. Evidence-based recommendations for pharmacologic intervention in the treatment of PMDD include serotonergic antidepressants or medications that suppress ovulation without reintroducing PMS-like symptoms [70]. Three selective serotonin reuptake inhibitors (SSRIs; fluoxetine, sertraline and paroxetine) have US FDA indications for the treatment of PMDD. In 2006, the FDA also approved an oral contraceptive (OC) that consists of 24 days of active pills followed by four placebo pills (24/4 regimen), comprised of a novel progestin, dropsirenone (3 mg) and a low dose of estrogen (20 mg of ethinyl estradiol) for the treatment of PMDD in women desiring contraception [71,72]. Serotonin norepinephrine reuptake inhibitors (SNRIs) have also shown efficacy in smaller studies [73]. Other medications that have demonstrated some utility in the treatment of PMS, but have not been studied specifically for PMDD, include GnRH agonists with low-dose estradiol and progestin add-back [74], the androgenic hormone danocrine [75], and high doses of transdermal estradiol with cyclic or intrauterine progestin for uterine protection [76].

Before starting any pharmacologic treatment, care should be taken to review any previous treatments. As PMDD affects reproductive-aged women, contraception and future plans for pregnancy must be discussed. In addition, a conversation should be held regarding management of side effects and possible teratogenicity if pregnancy should occur [74].

SSRIs, SNRIs & other serotonergic antidepressants

Serotonergic agents (SSRIs, SNRIs, atypical serotonergic antidepressants and serotonergic tricyclics) are considered to be effective treatments for PMDD. These agents alleviate symptoms in up to 60–80% of patients across multiple treatment trials and meta-analyses [77 –81]. Unique to patients with PMDD is their rapid response to these serotonergic agents, usually within the first menstrual cycle and generally within 1–2 days. This quick response differs from the treatment of depressive or anxiety disorders, where an effect may take up to 3–4 weeks to appear [70]. The rapid response to therapy among PMDD patients has allowed for intermittent luteal-phase dosing, as well as intermittent symptom-onset dosing [69,82]. The choice of continuous versus intermittent dosing is generally tailored to the individual woman, taking into account symptoms, adverse effects, treatment response and patient preferences [71]. When SSRIs were first evaluated for the treatment of PMDD, they were utilized with continuous daily dosing, but more recent studies have evaluated intermittent, luteal-phase dosing, starting at approximately the estimated time of ovulation and continuing for 14 days per month (Table 1).

Table 1.

Serotonergic medications for the treatment of premenstrual dysphoric disorder: summary of randomized controlled trials.

Medication	Dose (mg)	Outcome	Ref.
Continuous dosing
Fluoxetine	20	+	[88,96,183 –187]
Fluoxetine	60	+	[96,188]
Sertraline	50–150	+	[83,85,189]
Paroxetine	20	+	[86]
Paroxetine CR	12.5–25	+	[190,191]
Citalopram	Follicular: 5; luteal 10–30	+	[87]
Venlafaxine	20–200	+	[73]
Intermittent dosing
Fluoxetine	10 and 20	+	[188]
Fluoxetine	90	+	[192]
Sertraline	50–150	+	[85,115,193,194]
Paroxetine	10–30†	+	[86,89,195]
Paroxetine CR	12.5–25	+	[82,196]
Citalopram	10–30	+	[87]
Escitalopram	10–20	+	[90]

†

Steiner et al. found no relief of premenstrual dysphoric disorder symptoms when lower doses of paroxetine (10 mg) were used [89].

Improvement in premenstrual dysphoric disorder symptoms; CR: Controlled release.

A responder typically experiences a >50% reduction in PMDD symptoms, with this response rate to treatment being considerably greater than the placebo response rate [70]. In practice, incomplete responses can be improved by combining an SSRI with another agent, such as the OC pill or an anxiolytic, to address persistent physical or psychologic symptoms, but there are no published studies of these approaches [71]. For example, persistent anxiety on a SSRI can be mitigated by switching SSRIs or adding an anxiolytic during the symptomatic days. Residual physical symptoms, such as pain or bloating, can be managed with particular OCs, analgesics or a mild diuretic, such as the potassium-sparing drug, spironolactone.

Effectiveness of SSRIs in treatment of PMDD

SSRIs are the treatment of choice for severe PMS and PMDD given there efficacy as well as tolerability (Table 1) [69]. They have been shown to improve both emotional and physical symptoms of PMDD and have also demonstrated a positive effect on social functioning [16,83,84]. SSRIs are also the most well-studied psychotropic treatment of PMDD, with several meta-analyses confirming their efficacy, the most recent in 2013 [77 –80]. Nonserotonergic antidepressants are not effective for PMDD [69]. SSRIs are the only serotonergic medications the FDA has approved for the treatment of PMDD. The European Medicines Agency indicates that these drugs work, and certain SSRIs are approved in some countries, but neither intermittent nor continuous treatment is approved for use in the UK or continental Europe [74].

SSRIs: continuous versus luteal dosing

Although the most recent meta-analysis evaluating SSRIs in the treatment of PMDD found no difference in the effectiveness of continuous versus intermittent dosing, only three studies evaluating dosing regimens were included with substantial heterogeneity [77,85 –87]. In the 2008 meta-analysis, Shah et al. found continuous dosing to be more efficacious compared with intermittent dosing (odds ratio: 0.28 vs 0.55) [79]. Recent studies comparing dosing regimens have found that luteal-phase dosing is ineffective for some somatic symptoms, while irritability and mood swings are improved [88 –90]. Landen et al. reported that 80% of women on continuous therapy wanted to continue treatment, while 66% of women on intermittent therapy and 36% on placebo wanted to continue treatment [86]. Given that relatively few studies directly compare intermittent with continuous dosing for the treatment of PMDD, there are insufficient data to make concrete conclusions. Intermittent therapy is not associated with withdrawal symptoms and may have certain benefits, such as decreased costs, and side effects, such as weight gain and sexual dysfunction.

SSRIs: symptom-onset dosing

Symptom-onset dosing is a newer method of psychotropic treatment of PMDD and entails women taking medication when symptoms begin, or a few days before expected symptoms, and stopping at the onset of menses, or within 3 days after the onset of menses [28]. The theory behind this type of dosing is that there is significant patient variability in the time-to-onset and -offset of PMDD symptoms, and by tailoring a patient's medication regimen to their own cycle can further aid treatment [91]. Recent studies evaluating this symptom-onset dosing have yielded promising results [82,92 –94]. Specifically, Freeman et al. compared symptom-onset dosing to luteal-phase dosing and found that both dosing regimens significantly improved PMDD symptoms [92].

SSRIs dose-response studies

In the latest meta-analysis, there was consistent evidence that even low doses of SSRIs were effective, however, moderate doses were generally associated with larger effect size and a higher response rate [77]. Given the short onset of action of SSRIs, the onset of action should be expected during the first menstrual cycle of treatment. If no effect is seen, the dose may be increased in the next cycle if the patient is without negative side effects [95]. There is also evidence that a higher dose of a SSRI can be more effective in an intermittent dosing regimen. Eriksson et al. found that when comparing 10–20 mg of escitalopram, the 20-mg dose was superior in reducing mood and anxiety premenstrual symptoms [90]. Similarly, Steiner et al. found that when comparing 10–20mg of paroxetine, the higher dose was superior compared with placebo in alleviating severe premenstrual mood and anxiety symptoms [89]. The caveat to increasing doses of SSRIs for symptom relief, is the intensification of unwanted side effects that might cause patients to withdraw from therapy altogether. When Steiner et al. investigated high doses of fluoxetine, 33% dropped out of the study, while 86% reported at least one side effect [96].

Side effects: SSRIs

Side effects are common with SSRIs, but usually abate after a few days of treatment. The most common side effect is nausea and, for those patients on intermittent treatment, symptoms do not usually return after starting a new cycle [86,90]. Other common side effects include headache, fatigue, diarrhea, dizziness and decreased libido or anorgasmia [95]. Sexual side effects, such as reduced libido and anorgasmia, are disturbing for some patients and can persist throughout treatment, thus affecting relationships [97,98] and resulting in noncompliance [99]. For patients particularly affected by sexual side effects, intermittent dosing is helpful as patients are asymptomatic in the drug-free period [100]. The addition of other medications, such as buspirone, sildenafil or bupropion, can also counter the sexual side effects of SSRIs [85].

As pregnancy might occur while women with PMDD are being treated with SSRIs and SNRIs, adequate counseling should be provided regarding the possible risks of fetal exposure to serotonergic neuromodulators. To date, there is no compelling evidence that one particular SSRI or SNRI is safer or more dangerous in pregnancy [101]. More data exist on older drugs, such a fluoxetine, which may be preferred by some physicians. Many studies have addressed a possible increased risk of persistent pulmonary hypertension in the newborn with SSRI use. Most recently, this link has been partly invalidated by two well-designed studies, one multicenter retrospective cohort and one case-controlled study, both of which eliminated any recall bias [102,103]. Furthermore, the early evidence connecting paroxetine use and cardiac malformations has not been confirmed by prospectively ascertained data from the largest number of paroxetine exposures [104]. There are limitations of the methodology and inconsistency of the findings in the published studies, suggesting that the question of safety of SSRIs in pregnancy remains unanswered until large prospective studies are conducted [105 –107]. Of the SSRIs approved for treatment of PMDD, paroxetine is category D, suggesting proved human risk, while both fluoxetine and sertraline are category C, with less adverse risk. However, these categorizations may be outdated and are inconsistent with the latest data.

Serotonin norepinephrine reuptake inhibitors

SNRIs are less well studied, but have demonstrated success in treatment of PMDD. One randomized controlled trial (RCT) found that continuous dosing of venlafaxine was superior to placebo, with a response rate of 60% compared with 35% for placebo. Similar to treatment with SSRIs, treatment response was rapid with 80% of women experiencing symptom relief during their first treatment cycle [73]. However, in an open-label study using venlafaxine in intermittent dosing, there were flu-like symptoms after abruptly stopping venlafaxine [108]. Recently, two open-label studies reported improved symptoms of PMDD with continuous dosing of duloxetine 60 mg daily, but these results need to be replicated in RCTs [109,110].

Other CNS-acting drugs: anxiolytics

There is some reported success with anxiolytics in women with PMDD. Specifically, if a patient's symptoms are predominantly anxiety/tension and/or irritability, anxiolytics might be a good second-line therapy. While some studies have demonstrated a benefit with luteal-phase treatment with alprazolam, others do not show success [111 –114]. Anxiolytics are not first-line therapy as they have sedating properties in addition to the potential for abuse. Current recommendations are for benzodiazepine treatment only in the luteal phase to avoid abuse [95].

Buspirone is a 5-HT-1 partial agonist used for generalized anxiety disorder, which has demonstrated some success in the treatment of PMDD [115 –117]. Buspirone might be a helpful second drug for patients who suffer from decreased libido/anorgasmia with SSRIs, or even as a solo agent, given its low sexual side-effect profile. The response rate of anxiolytics is still below that of the first-line psychopharmacologic treatment, SSRIs.

Hormonal therapy

The goal of hormonal therapy in the treatment of PMDD is to suppress the hypothalamic–pituitary–gonadal axis and control sex steroid fluctuations in the luteal phase when patients are symptomatic. Different strategies have been tested for suppression of ovulation with: OCs, high-dose estrogen patches; GnRH agonists; danazol (a synthetic partial androgen); and surgical menopause with bilateral salpingo-oophorectomy (Table 2).

Table 2.

Ovulation suppression for treatment of premenstrual dysphoric disorder: summary of randomized controlled trials.

Medication	Dose	Add-back	Effect	Ref.
Oral contraceptive
DRSP/EE	3 mg/20 μg (24 days with treatment/4 days without)	–	+	[126 –128]
LNG/EE	90 μg/20 μg daily	–	+ †	[124,125]
GnRH analog
Depoluprolide	3.75 mg im. monthly	None	+	[142,143]
Gosrelin	3.6 mg im. monthly	None	+	[141]
	3.6 mg im. monthly	Estradiol valerate 2 mg daily plus NET 5 mg daily (day 21–28)	+
Histrelin	100 μg sc. daily	CEE (day 1–25) plus MPA 10 mg (day 16–25)	+ ‡	[144]
Depoluprolide	3.75 mg im. monthly	Tibilone 2.5 mg/day (at onset of symptoms)	+	[145]
Transdermal patch
Estradiol patch	100–200 μg continuous	–	+	[76,136]

†

Inconsistent results in other published trials.

‡

Other arms of the study with no benefit.

Improvement in premenstrual dysphoric disorder symptoms; CEE: Conjugated equine estrogen; DRSP: Drosperinone; EE: Ethinyl estradiol; GnRH: Gonadotropin-releasing hormone; im.: Intramuscular; LNG: Levonorgestrel; MPA: Medroxyprogesterone acetate; NET: Norethindrone; sc.: Subcutaneous.

Oral contraceptives

Although OCs are widely used for the treatment of the physical symptoms of PMS, they are generally ineffective in the treatment of PMDD [70,118]. Placebo-controlled trials have been scarce, and historically have had limited success in the treatment of PMDD or PMS [119,120]. In an epidemiologic study of women taking a variety of OCs, 12.3% of patients reported an improvement in mood and 71.4% reported no change in mood after starting OCs [121].

The dosing regimen and progestin formulation of OCs impact the potential reduction of PMDD symptoms. Bäckström et al. evaluated monophasic and triphasic OCs, and found that regimens containing desogestrol versus levono-gestrol had greater improvement in mood symptoms and that triphasic OCs were less effective than monophasic OCs [118].

The traditional ‘21/7’ OC regimens allow for continued endogenous hormonal fluctuation, which can mimic some of the physical symptoms of PMS [122]. Patients with PMDD report more symptoms during hormone-free days, suggesting that OCs with fewer hormone-free days are more effective [122,123]. Those OC formulations with 24 active pills and 4 placebo days have demonstrated a more complete suppression of folliculogenesis, but this does not in itself explain the improved symptom relief in PMDD patients [122]. Furthermore, Halbreich et al. demonstrated decreased PMDD symptoms with continuous daily levonorgestrol/ethinyl estradiol, but the results were modest [124]. A recent review of four studies evaluating continuous dosing with daily levonorgestrol (90 μg)/ethinyl estradiol (20 μg), showed some significant improvements in premenstrual symptoms, but the findings were inconsistent [125].

One novel OC comprised 3-mg drospirenone/20-mg ethinyl estradiol 24/4, showed a 50% decrease in PMDD symptoms in 48% of women ingesting active drug versus 36% in placebo [126]. In a crossover trial, Pearlstein et al. found that a positive response was noted in 62% of women with active preparation versus 32% with placebo [127]. Recently, a Cochrane review found that OCs containing drospirenone reduced PMDD symptoms, such as loss of productivity and impairment of social relationships, over a short timeframe [128]. In women under treatment with SSRIs for affective symptoms associated with PMDD, the addition of drospirenone-containing OCs has demonstrated benefit [129].

In theory, the success with this formulation lies in drospirenone, which binds to aldosterone and androgen receptors, potentially decreasing the somatic symptoms of bloating and breast tenderness, as well as acne and, perhaps, aggression/irritability. Spironolactone also has antial-dosterone properties and has been shown to relieve symptoms of PMS, notably breast pain and bloating [130,131].

There has been recent investigation into venous thromboembolism (VTE) occurrence with drosperinone-containing contraceptives. VTE risk is highest during the first months of pill usage. Given the usage of drosperinone in a noncontraceptive manner, these OCs are preferentially prescribed to women who are new to OCs and with a higher risk of VTE. An FDA review is currently ongoing, but the FDA labeling suggests an approximately 1.5-fold increased risk of blood clots for users of drosperinone-containing contraceptives, which is comparable to other progestins such as desogestrel and norgestimate [201]. To put this risk into perspective, the risk of developing deep vein thrombosis in women using drosperinone OCs is ten women in 10,000 compared with six women in 10,000 using other hormonal OCs [132,201]. This increased risk of VTE with drosperinone-containing OCs has not been confirmed in large observational studies or clinical trials. In fact, a large postmarketing observational study of over 50,000 European women did not find that women taking drosperinone-containing OCs had a higher risk of adverse cardiovascular events or VTE occurrence [133]. Furthermore, a recent meta-analysis found that all OCs conferred the same increased risk of VTE, except for levonorgestrel-containing OCs [134]. The epidemiologic studies prompting the FDA's warning have been criticized for failing to adjust for history of OC use, family history of thromboembolic events and BMI [135]. Although the verdict is still out whether drosperinone-containing OCs further increase the risks of VTEs, individualized risk assessment should be performed in all patients to identify women with increased risk, due to age, family history, BMI, hypertension and smoking.

High-dose transdermal estrogen

High doses of exogenous estrogen can also suppress the hypothalamic–pituitary–gonadal axis and thereby block ovulation. Two RCTs found women suffering from severe PMS had symptom improvement using 100–200-mg daily doses through a transdermal patch [76,136]. Given the risk of endometrial hyperplasia with unopposed estrogen, patients were given either norethisterone for 7 days per month or a levonorgesterol-containing intrauterine device [76,136]. The intrauterine device containing levornorgestrol is preferable in women with PMDD as systemic progesterone can cause PMS-like symptoms. Furthermore, the transdermal route of 100 μg of estrogen has a lower risk of VTE than equivalent doses given orally [137].

Danazol

Danazol is a synthetic partial androgen antagonist/agonist and gonadotropin inhibitor that also prevents PMS symptoms when dosed to inhibit ovulation. Unfortunately, its ungainly side effects of acne, hirsutism and possible teratogenicity make this an unpopular first-line drug [28]. Sarno et al. evaluated 14 patients with PMS who were randomized in a double-blind, crossover design to receive low-dose danazol (200 mg) or placebo. Those taking danazol had significantly fewer symptoms compared with placebo when ovulation was inhibited [75]. In another study, lack of improvement in symptoms and negative side effects led to early withdrawal [138]. Danazol can reduce premenstrual mastalgia when administered in the luteal phase [139], but this has also been accomplished with luteal administration of toremefine, an estrogen receptor antagonist [140].

GnRH agonists

GnRH agonism successfully suppresses ovulation by downregulating pituitary gonadotropin secretion and, ultimately, eliminating pulsatile luteinizing hormone and follicle-stimulating hormone secretion. Three RCTs using GnRH analogs have demonstrated improved physical, emotional and behavioral symptoms in women with severe PMS [141 –143]. Interestingly, women with severe premenstrual depression had no improvement of symptoms, suggesting that women with depressive symptoms might be adversely affected by the hypoestrogenic milieu created by GnRH analogs [143]. To bypass the ‘medical menopause’ created by GnRH analogs, low-dose estrogen or tibolone (an agent with estrogenic, androgenic and progestogenic effects) can be administered to decrease the negative impact of estrogen deficiency on mood and vasomotor symptoms. In addition, as there is an increased risk of osteoporosis and coronary artery disease with the hypoestrogenic state afforded by GnRH agonist therapy, tibolone or estradiol add-back therapy can potentially limit the deleterious effects of hypoestrogenism on bone and cardiac health [141,144 –146]. Leather et al. demonstrated that some patients had a recurrence of symptoms with add-back therapy that included a progestin [141]. A more recent meta-analysis evaluating GnRH analogs with add-back therapy with tibolone improved PMDD symptoms and was less likely to reintroduce premenstrual symptoms when compared with cyclical estrogen and progesterone [42]. Progestin can be administered in the form of an intrauterine device if oral therapy is not tolerated. Furthermore, Mitwally et al. found that GnRH agonist administration with add-back hormonal therapy prevented bone loss, as well as controlled symptoms in severe PMS [146]. However, as long-term studies are lacking, GnRH agonist therapy, even with add-back, is considered a third-line therapy. A 3–6 month trial of GnRH administration can be useful in order to help distinguish an exacerbation of an underlying affective disorder from superimposed PMDD, or as a test of the potential outcome of surgical oophorectomy.

Surgical menopause

Removal of bilateral ovaries with or without a hysterectomy is a last-resort measure. When more conservative treatments have failed, surgical menopause can be considered for women with severe, debilitating PMDD [37 –39]. After bilateral salpingo-oophorectomy, it is important to replace estrogen until the age of natural menopause to prevent complications of premature menopause, such as osteoporosis and cardiac disease [146]. If the uterus is retained after bilateral salpingo-oophorectomy, progesterone is required to prevent endometrial hyperplasia, which may reintroduce PMS symptoms; therefore, the addition of hysterectomy is preferable. Prior to hysterectomy and oophrectomy, a 3 −6 month trial of a GnRH agonist with estrogen replacement alone is prudent to predict treatment response to surgery and to ensure estrogen replacement is well tolerated, since the long-term effects of estrogen deficiency are of grave concern [147].

Nonpharmacologic & complementary & alternative strategies

Dietary modification

Dietary changes during the luteal phase may result in symptomatic relief for PMS, although no diet modifications have been systematically evaluated, especially for PMDD [69,148]. It is thought that caffeine, sugar and alcohol intake may increase PMS symptoms [28,149]. Increasing complex carbohydrate intake premenstrually has been shown to improve mood, carbohydrate craving and memory in PMS, by potentially i ncreasing tryptophan, a precursor to serotonin [150].

Calcium/vitamin B6

Calcium is one dietary supplement that has the most evidence for the treatment of PMS, although it has not been studied for PMDD specifically [95,151]. Calcium supplementation is thought to regulate calcium homeostasis, specifically as it fluctuates during the menstrual cycle. Furthermore, hypocalcemia has been associated with affective disturbances similar to symptoms of PMD [152]. In two RCTs, calcium supplementation (1200 mg/day in divided doses) was found to manage PMS symptoms, such as mood and physical complaints [152,153].

The effect of vitamin B6 supplementation is more equivocal, with no studies for PMDD and only a few studies finding marginal reduction in symptoms [154]. Caution should be taken in doses >100 mg of vitamin B6, which can cause peripheral neuropathy [69].

Herbal treatments: agnus castus (chasteberry) & Hypericum perforatum (St John's wort)

Agnus castus (chasteberry) has demonstrated promise in the treatment of PMDD. A RCT of chasteberry found superior benefit compared with placebo, with emotional as well as somatic symptoms [155]. Some data find the response rate to chasteberry to be equivalent to that of fluoxetine [156]. Hypericum perforatum (St John's wort) may also have a beneficial effect when compared with placebo in a small pilot study [157,158]. Caution should be used with St John's wort given its known interaction with SSRIs and other medications, as well as its possible interference with the efficacy of OCs [28]. Pharmacologic interactions between St John's wort and SSRIs are probably due to altered metabolism and transport caused by the major active components in St John's wort. St John's wort is a strong inducer of CYP450 isoenzymes CYP3A4, CYP2C9 and CYP1A2, and transport protein P-GP. These interactions of SSRIs and St John's wort are associated with an increased risk of serotonin excess (e.g., serotonin syndrome, characterized by at least three of the following: confusion, agitation, hyper-reflexia, diaphoresis, lack of coordination, fever, coma, flushing or rhabdomyoiysis) [159]. There is also a reduction of the bioavailability of OCs (increased clearance of progesterone and a reduction in the half-life of ethinyl estradiol) when OC pills are taken with St John's wort [160]. The increased metabolism of hormonal contraceptives related, in part, to increased CYP3A4 activity [160]. There can be up to a 15% reduction in the dose of OCs resulting in increased rates of breakthrough bleeding, follicle growth, probable ovulation and unplanned pregnancies [160].

Cognitive-behavior therapy, relaxation response & acupuncture

Cognitive–behavior therapy (CBT) is a type of psychotherapy where negative or maladaptive cognitive experiences or thoughts are identified and corrected, promoting behavioral change [161]. Specifically, CBT may include modification of irrational behavior and coping strategies. Reviews of RCTs on CBT for the treatment of PMS and PMDD show weak superiority when compared with placebo [162,163], and only one has evaluated CBT in women with PMDD [163]. CBT has proven to be a successful adjunct to SSRI therapy. When CBT alone was compared with SSRI alone, or in combination, all CBT groups demonstrated significant improvement in PMS symptoms after 6 months of treatment. Furthermore, those treatment arms exposed to CBT had superior long-term improvement [161].

Acupuncture, Qi therapy, reflexology, massage, krill oil, lavender oil, Chinese herbs or transmagnetic stimulation may help symptoms, but these treatments should only be offered after adequate evidence exists [95].

Exercise

It is commonly thought that exercise improves premenstrual symptoms through elevation of β-endorphin levels; however, there is little evidence to confirm this, with only one small RCT conducted [164]. Daley commented on the paucity in literature regarding exercise and reduction of PMSs. In the four interventional studies reviewed, Daley found that women reported reduction in PMS symptomatology after exercise [165]. The American College of Obstetricians and Gynecologists recommends exercise for PMS, but further studies are needed to substantiate this recommendation [7].

Alteration of sleep & circadian rhythm: bright-light therapy & sleep deprivation

There is evidence that women with PMDD have altered biological rhythms of body temperature and melatonin secretion [166]. Specifically, women with PMDD have decreased melatonin secretion similar to patients with major depressive disorder, suggesting a phase advance of circadian rhythms. Sleep deprivation has been proposed to correct the altered circadian rhythms of women with PMDD by affecting the sleep–wake cycle. Studies have found that sleep deprivation increases total sleep time, rapid eye movement sleep and improvement of mood in women with PMDD [166 –168]. Bright-light therapy has been very promising in alleviating symptoms of PMDD. Parry et al. first demonstrated that bright-light therapy in the early morning and evening could alleviate PMDD symptoms [169]. A follow-up study by Lam et al. found that bright white light in the evening also improved symptoms [170]. A meta-analysis of bright-light therapy on depression associated with PMDD found a great deal of heterogeneity in the small numbers of studies performed [171]. More rigorous research needs to be performed in this field to validate bright therapy as a proven treatment of PMDD.

Conclusion

To date, the most effective treatment of PMDD has been neuromodulation through SSRIs. Numerous well-designed trials have elucidated an improvement in PMDD symptoms with serotonergic modulation in women with the disease. For those women in whom symptoms of irritability, depressed mood, lability and anxiety predominate, SSRIs are the first-line therapy.

Although the goal of hormonal treatment is to suppress the gonadal steroid cyclicity that triggers symptoms of PMDD, most OCs have had inconsistent results in alleviating symptoms. Drospirenone-containing OCs have shown efficacy in reducing PMDD symptoms, as well as improving loss of productivity and impairment of social relationships, and are also considered a first-line therapy. High-dose transdermal estrogen and cyclic or intrauterine progestin are also useful as first- or second-line therapy. Although GnRH agonism has also demonstrated success in the treatment of PMS, it is a third-line therapy and should include add-back therapy given the negative sequelae of the hypoestrogenic state on the bone and heart in premenopausal women.

Nonpharmacologic treatments have demonstrated less improvement in the treatment of PMDD compared with SSRIs or suppression of ovulation. These treatments are rarely studied in a rigorous manner, making the evidence for their use less substantial. Calcium supplementation has demonstrated the most promise in treating PMS. Chasteberry has also demonstrated success compared with placebo in the alleviation of symptoms. Potential benefits may exist from behavioral modifications, such as a change in diet, stress reduction and exercise. There is substantial evidence that bright-light therapy and sleep deprivation can reset altered circadian rhythms and alleviate symptoms in women with PMDD. CBT is also probably efficacious and may have an additive effect with SSRI therapy, but this needs to be studied more meticulously.

In the treatment of women suffering from PMDD, care must be taken to optimize symptom relief without incurring debilitating side effects. Since women with PMDD are of reproductive age, contraception should also be discussed and a knowledge of current fertility desires must be ascertained.

Moving PMDD to a distinct mood disorder in the DSM-V could lead to a more rigorous characterization of women participating in clinical trials and research studies, focusing on pathophysiology and treatment [5]. As we continue to learn more about this disorder, treatment will probably become more effective and specific to PMDD.

Future perspective

The treatment of PMDD is hindered by incomplete knowledge regarding its neurobiological basis. PMDD is clearly linked to the physiologic process of ovulation and the ensuing dynamics of the luteal phase of the menstrual cycle. Furthermore, there is ample evidence documenting the role of the serotonergic system in the pathophysiology of this disorder [172]. SSRIs are a first-line therapy for PMDD, with 60–80% of women considered as ‘responders’, experiencing at least a 50% decrease in their symptoms; however, after subtracting the percentage of women who respond to placebo in the RCTs, the percentage of women who actually respond to a drug is closer to 50% [173], and 30–40% of women with PMDD do not completely respond to pharmacologic treatment with serotonergic agents. A similar calculation can be made for the other first-line treatment approach, an OC formulation containing 3 mg of dropsirenone and 20 μg of ethinyl estradiol in a 24/4 regimen. The rise and fall of endogenous sex steroids can be prevented with a continuous intake of an OC, but surprisingly, even when the exogenous steroid concentration is stable, maintained by a constant dose of a monophasic preparation of a synthetic estrogen and a progestin, symptoms are not reliably and invariably improved [124].

This conundrum has yet to be resolved and highlights the fact that there is still much to be learned about the effect of estrogens and progestagens on the brain and on behavior. Further study of estrogen and progesterone activity on intracellular and membrane hormone receptors across the menstrual cycle in women with and without PMDD, may shed light on the differential response to fluctuating sex steroids in PMDD. Discoveries related to neuroendocrine modulation of the menstrual cycle, or the role of polymorphisms in hormone receptors or neurotransmitters will have therapeutic ramifications for treatments with novel selective estrogen or progesterone receptor modulators, or other neuroactive compounds [174,175].

The symptoms, including profound irritability, affective irritability, depressed mood, anxiety, impulsive behavior, and cognitive and sleep disturbances, place PMDD within the spectrum of affective illness. Considerable evidence has indicated that PMDD is not just a variant of depression and anxiety disorder, and that information on the diagnosis, treatment and validation of PMDD is adequate for its qualification as a full category in the DSM-V [5]. The timing, nature of the most commonly reported symptoms, heritability estimates, lack of shared genetic and environmental variance and a distinct therapeutic response profile all separate PMDD from affective or anxiety disorders [5,176].

A recent review stated that “neuroimaging studies are in their infancy with regard to revealing the neurocircuitry and neurochemistry of PMDD” and highlighted the need for biological research on PMDD to identify effective therapies [5]. A possible hypothesis that we are currently testing is whether the core affective symptoms of PMDD reflect a luteal phase-related deficit in emotion regulation. Further studies assessing neural circuitry will hopefully yield knowledge about the neural basis of emotion control and dysregulation in PMDD. Although effects of the menstrual cycle on neural responses to emotion provocation have been noted in healthy women [176,177], cycle effects on emotion regulation or its neural substrates have not been well studied in women with PMDD. Positive results would identify defective emotion regulation and the relevant circuits as therapeutic targets, and would provide biomarkers and a platform for the evaluation of new treatments for PMDD.

In the future, with the goal to improve therapeutic outcome, the identification of endophenotypes for PMDD may allow for the development of personalized pharmacologic therapy based on pharmogenetic data. Endophenotypes are created by separating the behavioral symptoms of PMDD into distinct phenotypes with definite genetic connections. In the treatment of various psychiatric disorders, the combination of neuroimaging, neuroendocrinology and genetic studies shows promise in the search for successful personalized therapy based on genome types and biomarkers. For example, in the case of major depressive disorders, genetic variants have been identified that are associated with different presentations of depression and with response to antidepressant drugs. Neuroimaging studies have also demonstrated that these genetic variants affect emotional processing, and are associated with changes in activity in brain regions that have been implicated in major depression and with specific antidepressant drug responses. It has been suggested that the neural alterations seen in major depressive disorder might be reflected in the serum, and could potentially be useful biomarkers for depression. Studies have investigated genetic variants affecting the CYP450 isoenzyme system (which have an effect on antidepressant metabolism), the serotonin transporter gene, and alterations in enzymes that are important in the degradation of monoamines (e.g., serotonin), inflammatory cytokines and neurotrophic factors [178,179].

Executive summary

Premenstrual dysphoric disorder: definitions & epidemiology

Diagnosis of premenstrual dysphoric disorder (PMDD) requires a pattern of psychologic, physical and/or behavioral symptoms that begin during the luteal phase and resolve completely during menses.

While 20–30% of women will be affected by moderate-to-severe symptoms meeting criteria of premenstrual syndrome, 3–8% will meet the criteria for PMDD delineated by the Diagnostic and Statistical Manual of Mental Disorders V.

Women with PMDD have a 50–78% lifetime incidence of other psychiatric disorders.

Pathophysiology of PMDD

Given symptom onset triggered by ovulation, it has been established that fluctuations in sex steroids are involved in the pathogenesis of PMDD.

The GABA neurotransmitter system is believed to be altered in women with PMDD, with altered functional sensitivity of the GABA_Areceptor.

Lowered serotonin activity is etiologic to PMDD, given the relevant research and specific response to serotonergic agents.

Brain neurocircuitry may be altered in women with PMDD, with recent studies indicating abnormal brain activation in the dorsolateral prefrontal cortex and cerebellum compared with healthy controls.

Pharmacologic treatment: neuromodulation

The US FDA has approved three selective serotonin reuptake inhibitors (SSRIs) for the treatment of PMDD (fluoxetine, sertraline and paroxetine), and each have demonstrated improvement of PMDD symptoms in several randomized controlled trials.

Continuous dosing and luteal phase dosing of serotonergic drugs have been found to be equally effective in alleviating symptoms.

Efficacy is generally demonstrated at the lower end of the recommended SSRI dosing.

Second-line treatment or treatment of residual anxiety after SSRI therapy includes luteal phase administration of anxiolytics, such as buspirone and benzodiazepines. Long-term benzodiazepine use can exacerbate depression.

Pharmacologic treatment: hormonal therapy

Oral contraceptives (OCs) with standard dosing regimen of 21 days of treatment with 7 hormone-free days have not been shown to be effective in the treatment of PMDD.

OCs given in a continuous daily regimen with no hormone-free days have demonstrated possible success in PMDD treatment.

OCs containing dropsirenone and 20 μg of ethinyl estradiol in a 24/4 dosing schedule are approved by the FDA for the treatment of PMDD in women who are also seeking contraception. These OCs demonstrated alleviation of PMDD symptoms in several randomized controlled trials and meta-analyses.

High-dose transdermal estrogen blocks ovulation and improves PMDD symptoms, but requires a progestin to protect the endometrium.

Danazol, a synthetic partial androgen antagonist/agonist, and gonadotropin inhibitor can relieve PMDD symptoms, but has unwanted side effects of hirsutism and acne, and can virilize a fetus if conception occurs during therapy.

GnRH agonists are a third-line therapy that should be used with add-back estrogen and progestin therapy to alleviate negative health consequences of hypoestrogensim.

Surgical menopause should be a last resort for young women and used only in very limited situations.

Other treatments

Calcium has improved symptoms in women suffering from premenstrual syndrome and may help women with PMDD.

Bright-light therapy can be effective for PMDD.

Chasteberry has been found in small studies to have superior benefit when compared with placebo, with emotional and somatic symptoms of PMDD.

Behavior modifications, such as diet, exercise and relaxation techniques, have proven successful in treatment of PMS, but have not been studied rigorously for PMDD.

Congnitive-behaviour therapy has been found to have modest improvement in PMDD symptoms, but may be more effective as an adjunct to serotonergic therapy in women suffering from behavioral symptoms of PMDD.

Future perspective

Future targeted treatments should focus on the estimated 30–40% of women suffering from PMDD that do not respond to, or who can not tolerate, current pharmacologic and or behavioral treatments.

Study of neuroendocrine modulation of the menstrual cycle, with attention to ovarian steroid activity on membrane and intracellular hormone and other neurotransmitter receptors, could lead to novel therapeutic targets.

Research on the neural circuitry in women with PMDD can yield knowledge about the neural basis of emotional control and dysregulation in PMDD, which can potentially lead to targeted treatments if significant pathology is found.

The search for endophenotypes in PMDD, by separating the behavioral symptoms of PMDD into distinct phenotypes with definite genetic connections, might guide personalized and targeted pharmacologic therapy.

This approach has not yet been explored adequately for PMDD. One relevant investigation that demonstrated the potential of this approach investigated phenotypic profiles related to stress and pain in women with history of PMDD and major depressive disorder [14]. Biomarkers related to the sympathetic nervous system, hypothalamic–pituitary axis and pain showed, not only unique phenotypic differences, but also important common features. Women with PMDD, with or without a history of major depressive disorder, demonstrated blunted stress reactivity compared with control women when assessing biomarkers related to sympathetic nervous system activation. However, there was no evidence for heightened sensitivity to experimental pain in women with PMDD after controlling for a history of major depressive disorder [180].

Thus far, serotonin-related phenotypes, such as variation in the serotonin transporter gene [181] and in the transcription factor AP-2 β, have not been found in women with PMDD [182]. Success in this area will help clarify the etiology of the symptoms of PMDD, and provide biomarkers for assessing behavioral and pharmacological interventions to ameliorate this disorder.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

References

Papers of special note have been highlighted as: • of interest

of considerable interest

O'Brien

Bäckström

Brown

Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal Consensus. Arch. Womens Ment. Health 14(1), 13–21 (2011).

Excellent discussion of the diagnostic criteria for premenstrual disorders.

Halbreich

Bäckström

Eriksson

Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol. Endocrinol. 23(3), 123–130 (2007).

Hylan

Sundell

Judge

. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J. Womens Health Gend. Based Med. 8(8), 1043–1052 (1999).

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). APA, Washington, DC, USA (1994).

Epperson

Steiner

Hartlage

Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am. J. Psychiatry 169(5), 465–475 (2012).

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th Edition). APA, Washington, DC, USA (2013).

10.

Excellent discussion of the rationale for including premenstrual dysphoric disorder in the Diagnostic and Statistical Manual of Mental Disorders V.

11.

American College of Obstetricians and Gynecologists. Premenstrual syndrome. ACOG Practice Bulletin 15 (2000).

12.

Royal College of Obstetricians and Gynecologists. Management of Premenstrual Syndrome. Green-top guidelines, London, UK (2007).

13.

Halbriech

Borenstein

Pearlstein

Kahn

. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28(Suppl. 3), 1–23 (2003).

14.

Dennerstein

Lehert

Heinemann

. Epidemiology of premenstrual symptoms and disorders. Menopause Int. 18(2), 48–51 (2012).

15.

Wittchen

Becker

Leib

Krause

. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol. Med. 32(1), 119–132 (2002).

16.

Bhatia

. Diagnosis and treatment of premenstrual dysphoric disorder. Am. Fam. Physician 66(7), 1239–1248 (2002).

17.

Pearlstein

Frank

Rivera-Tovar

Thoft

Jacobs

Mieczkowski

. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J. Affect. Disord. 20(2), 129–134 (1990).

18.

Praschak-Reider

Willeit

Neumeister

Prevalence of premenstrual dyshporic disorder in female patients with seasonal affective disorder. J. Affect. Disord. 63(1–3), 239–242 (2001).

19.

Bancroft

Rennie

Warner

. Vulnerability to perimenstrual mood change: the relevance of a past history of depressive disorder. Psychosom. Med. 56(3), 225–231 (1994).

20.

Kim

Gyulai

Freeman

Morrison

Baldassano

Dube

. Premenstrual dysphoric disorder and psychiatric co-morbidity. Arch. Womens Ment. Health 7(1), 37–47 (2003).

21.

Important review of comorbidity in premenstrual dysphoric disorder in psychiatric diagnosis.

22.

Severino

Yonkers

. A literature review of psychotic symptoms associated with the premenstruum. Psychosomatics 34(4), 299–306 (1993).

23.

Pearlstein

Halbreich

Batzar

Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J. Clin. Psychiatry 61(2), 101–109 (2000).

24.

Rapkin

Winer

. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert. Rev. Pharmacoecon. Outcomes Res. 9(2), 157–170 (2009).

25.

Robinson

Swindle

. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J. Womens Health Gend. Based Med. 9(7), 757–768 (2000).

26.

Heinemann

Minh

Heinemann

Lindemann

Filonenko

. Intercountry assessment of the impact of severe premenstrual disorders on work and daily activities. Health Care Women Int. 33(2), 109–124 (2012).

27.

Heinemann

Minh

Filonenko

Uhl-Hochgraber

. Explorative evaluation of the impact of severe premenstrual disorder on work absenteeism and productivity. Womens Health Issues 20(1), 58–65 (2010).

28.

Borenstein

Chiou

Dean

Wong

Wade

. Estimating direct and indirect costs of premenstrual syndrome. J. Occup. Environ. Med. 47(1), 26–33 (2005).

29.

Borenstein

Dena

Leifke

Korner

Yonkers

. Differences in symptom scores and health outcomes in premenstrual syndrome. J. Womens Health (Larchmt) 16(8), 1139–1144 (2007).

30.

Yang

Wallenstein

Hagan

Guo

Chang

Kornstein

. Burden of premenstrual dysphoric disorder on health-related quality of life. J. Womens Health (Larchmt.) 17(1), 113–121 (2008).

31.

Pilver

Libby

Hoff

. Premenstrual dysphoric disorder as a correlate of suicidal ideation, plans, and attempts among a nationally representative sample. Soc. Psychiatry Psychiatr. Epidemiol. 48(3), 437–446 (2013).

32.

Chaturvedi

Chandra

Gururaj

Pandian

Beena

. Suicidal ideas during premenstrual phase. J. Affect. Disord. 34(3), 193–199 (1995).

33.

Cunningham

Yonkers

O'Brien

Eriksson

. Update on research and treatment of premenstrual dysphoric disorder. Harv. Rev. Psychiatry 17(2), 120–137 (2009).

34.

Borenstein

Dean

Yonkers

Endicott

. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet. Gynecol. 109(5), 1068–1075 (2007).

35.

Soares

Cohen

. Association between premenstrual syndrome and depression. J. Clin. Pyschiatry 61(9), 677–678 (2000).

36.

Endicott

Nee

Harrison

. Daily record of severity of problems (DRSP): reliability and validity. Arch. Womens Ment. Health 9(1), 41–49 (2006).

37.

Steiner

MacDougall

Brown

. The premenstrual symptoms screening tool (PSST) for clinicians. Arch. Womens Ment. Health 6(3), 203–209 (2003).

38.

Rapkin

Mikacich

. Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents: diagnosis and pharmacological treatment. Paediatr. Drugs 15(3), 191–202 (2013).

39.

Review of diagnosis and management of premenstrual disorders in adolescent populations.

40.

Ross

Steiner

. A biopsychosocial approach to premenstrual dysphoric disorder. Psychiatr. Clin. North Am. 26(3), 539–546 (2003).

41.

Perkonigg

Yonkers

Pfiste

Lieb

Wittchen

. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J. Clin. Psychiatry 65(10), 314–322 (2004).

42.

Hammarback

Ekholm

Bacstrom

. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol. (Copenh.) 125(2), 132–137 (1991).

43.

Casper

Hearn

. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am. J. Obstet. Gynecol. 162(1), 105–109 (1990).

44.

Casson

Hahn

Van Vugt

Reid

. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am. J. Obstet. Gynecol. 162(1), 99–105 (1990).

45.

Cronje

Vashisht

Studd

. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum. Reprod. 19(9), 2152–2155 (2004).

46.

Hammarback

Bäckström

. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta. Obstet. Gynecol. Scand. 67(2), 159–166 (1988).

47.

Sundstrom

Nyberg

Bixo

. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet. Gynecol. Scand. 78(10), 891–899 (1999).

48.

Wyatt

Dimmok

Ismail

Jones

O'Brien

. The effectiveness of GnRHa with and without ‘add-back’ therapy in treatment premenstrual syndrome: a meta analysis. BJOG 111(6), 585–593 (2004).

49.

Excellent medical analysis of gonadotropin-releasing hormone therapy.

50.

Schmidt

Nieman

Danaceau

Adama

Rubinow

. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med. 338(4), 256–257 (1998).

51.

Interesting study highlighting the role of estrogen and progesterone in the genesis of premenstrual syndrome symptoms.

52.

Majewska

Harrison

Schwartz

Barker

Paul

. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232(4753), 1004–1007 (1986).

53.

Basis study outlining effects of progesterone metabolites on the GABA receptor.

54.

Rabow

Russek

Farb

. From ion currents to genomic analysis: recent advances in G ABAA receptor research. Synapse 21(3), 189–274 (1995).

55.

Rapkin

Morgan

Goldman

Brann

Simone

Mahesh

. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol. 90(5), 709–714 (1997).

56.

Schmidt

Purdy

Moore

Paul

Rubnow

. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J. Clin. Endocrinol. Metab. 79(5), 1256–1260 (1994).

57.

Klatzkin

Morro

Light

Pedersen

Girdler

. Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone. Psychoneuroendocrinology 31(10), 1208–1219 (2006).

58.

Poromaa

Sundström I

Smith

Gulinello

. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch. Womens Ment. Health 6(1), 23–41 (2003).

59.

*Comprehensive review of the effect of progesterone on GABA receptors.

60.

Kaura

Ingram

Garside

Young

Judge

. The progesterone metabolite allopregnanolone potentiates GABA_A receptor-mediated inhibition of 5-HT neuronal activity. Eur. J. Neuropsychopharmacol. 17(2), 108–115(2007).

61.

Sundstrom

Ashbrook

Bäckström

. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 22(1), 25–28 (1997).

62.

Birzniece

Bäckström

Johansson

Neuroactive steroid effects on cognitive functions with a focus on serotonin and GABA systems. Brain Res. Rev. 51(2), 212–239 (2006).

63.

Follesa

Concas

Porcu

Role of allopregnanolone in regulation of GABA(A) receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Res. Brain Res. Rev. 37(1–3), 81–90 (2001).

64.

Rojansky

Halbreich

Zander

Barkai

Goldstein

. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynaecol. Obstet. Invest. 31(3), 146–152 (1991).

65.

Menkes

Coates

Fawcett

. Acute tryptophan depletion aggravates premenstrual syndrome. J. Affect. Disord. 32(1), 37–44 (1994).

66.

Roca

Schmidt

Smith

Danaceau

Murphy

Rubinow

. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am. J. Psychiatry 159(11), 1876–1881 (2002).

67.

Ashby

Carr

Cook

Steptoe

Franks

. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol. Psychiatry 24(2), 225–233 (1988).

68.

Rapkin

Edelmuth

Chang

Reading

McGuire

. Whole-blood serotonin in premenstrual syndrome. Obstet. Gynecol. 70(4), 533–537 (1987).

69.

Biegon

McEwen

. Modulation by estradiol of serotonin receptors in brain. J. Neurosci. 2(2), 199–205 (1982).

70.

Eriksson

Wall

Marreinsdottir

Mood changes correlate to changes in brain serotonin precursor trafficking them with premenstrual dysphoria. Psychiatry Res. 146(2), 107–116 (2006).

71.

Smith

Adams

Schmidt

Rubinow

Wassermann

. Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biol. Psychiatry 54(7), 757–762 (2003).

72.

Epperson

Pittman

Czarkowski

Stiklus

Krystal

Grillon

. Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology 32(10), 2190–2198 (2007).

73.

Kask

Gulinello

Bäckström

Geyer

Sundström-Poromaa

. Patients with premenstrual dysphoric disorder have increased startle responses across both cycle phases and lower levels of prepulse inhibition during he late luteal phase of the menstrual. Neuropsychopharmacology 33(9), 2283–2290 (2008).

74.

Bannbers

Kask

Wikstrom

Risbrough

Poromaa

. Patients with premenstrual dysphoric disorder have increased startle modulation during anticipation in the late luteal phase period in comparison to control subjects. Psychoneuroendocrinology 36(8), 1184–1192 (2011).

75.

Epperson

. Premenstrual dysphoric disorder and the brain. Am. J. Psychiatry 170(3) 248–252 (2013).

76.

Rapkin

Berman

Mandelkern

Silverman

Morgan

London

. Neuroimaging evidence of cerebellar involvement in premenstrual dysphoric disorder. Biol. Psychiatry 69(4), 374–380 (2011).

77.

Berman

London

Morgan

Rapkin

. Elevated gray matter volume of the emotional cerebellum in women with premenstrual dysphoric disorder. J. Affect. Disord. 146(2), 266–271 (2013).

78.

Baller

Wei

Kohn

Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study. Am. J. Psychiatry 170(3), 305–314 (2013).

79.

Steiner

Pearlstein

Cohen

Expert guidelines for the treatment of severe PMS, PMDD, and cormorbidities: the role of SSRIs. J. Womens Health (Larchmt.) 15(1), 57–69 (2006).

80.

Rapkin

Winer

. The pharmacologic management of premenstrual dysphoric disorder. Expert. Opin. Pharmacother. 9(3), 429–445 (2008).

81.

Pearlstein

. Psychotropic medications and other non-hormonal treatments for premenstrual disorders. Menopause Int. 18(2), 60–64 (2012).

82.

Yonkers

Pearlstein

Fayyad

Gillespie

. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J. Affect. Disord. 85(3), 317–321 (2005).

83.

Freeman

Rickels

Yonkers

Kunz

McPherson

Upton

. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gynecol. 98(5 Pt 1), 737–744 (2001).

84.

O'Brien

Rapkin

Dennerstein

Nevatte

. Diagnosis and management of premenstrual disorders. BMJ 342, d2994 (2011).

85.

Sarno

Jr Miller

Jr Lundblad

. Premenstrual syndrome: beneficial effects of periodic, low-dose danazol. Obstet. Gynecol. 70(1), 33–36 (1987).

86.

Watson

Studd

Savvas

Garnett

Baber

. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 2(8665), 730–732 (1989).

87.

Marjoribanks

Brown

O'Brien

Wyatt

. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. 6, CD001396 (2013).

88.

Brown

O'Brien

Marjoribanks

Wyatt

. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. 2, CD001396 (2009).

89.

Recent review of selective serotonin reuptake inhibitors for the treatment of premenstrual syndrome.

90.

Shah

Jones

Aperi

Shemtov

Karne

Borenstein

. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet. Gynecol. 111(5), 1175–1182 (2008).

91.

Wyatt

Dimmock

O'Brien

. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. 4, CD001396 (2002).

92.

Dimmock

Wyatt

Jones

O'Brien

. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356(9236), 1131–1136 (2000).

93.

Yonkers

Holthausen

Poschman

Howell

. Symptom-onset treatment for women with premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 26(2), 198–202 (2006).

94.

Yonkers

Halbreich

Freeman

Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 278(12), 983–988 (1997).

95.

Steiner

Brown

Trzepacz

Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch. Women Ment. Health 6(1), 71–77 (2003).

96.

Freeman

Rickels

Sondheimer

Polansky

Xiao

. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am. J. Psychiatry 161(2), 343–351 (2004).

97.

Landen

Nissbrandt

Allgulander

Sorvik

Ysander

Eriksson

. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 32(1), 153–161 (2007).

98.

Wikander

Sundblad

Andersch

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phase more effective than continuous meidcaiton throughout the menstrual cycle?

J. Clin. Psychopharmacol 18(5), 390–398 (1998).

99.

Pearlstein

Stone

Lund

Scheft

Ziotnick

Brown

. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J. Clin. Psychopharmacology 17(4), 261–266 (1997).

100.

Steiner

Ravidnran

LeMelledo

Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. J. Clin. Psychiatry 69(6), 991–998 (2008).

101.

Eriksson

Ekman

Sinclair

Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J. Clin. Psychopharmacology 28(2), 195–202 (2008).

102.

Pearlstein

Yonkers

Rayyad

Gillespie

. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J. Affect. Disord. 85(3), 275–282 (2005).

103.

Freeman

Sondheimer

Sammel

Ferdousi

Lin

. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J. Clin. Psychiatry 66(6), 769–773 (2005).

104.

Kornstein

Pearlstein

Fayyad

Farfel

Gillespie

. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J. Clin. Psychiatry 67, 1624–1632 (2006).

105.

Ravindran

Woods

Steiner

Ravindran

. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Arch. Womens Ment. Health 10(3), 125–127 (2007).

106.

Nevatte

O'Brien

PMS

Bäckström

ISPMD consensus on the management of premenstrual disorders. Arch. Womens Ment. Health 16(4), 279–291 (2013).

107.

Steiner

Steinberg

Stewart

Fluoxetine in the treatment premenstrual dysphoria. N. Engl. J. Med. 332(23), 1529–1534 (1995).

108.

Howland

. Managing common side effects of SSRIs. J. Psychosoc. Nurs. Ment. Health Serv. 45(2), 15–18 (2007).

109.

Moret

Isaac

Briley

. Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J. Psychopharm. 23, 967–974 (2009).

110.

Nurnberg

. An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. Drugs Today 44, 147–168 (2008).

111.

Sunblad

Wikander

Andersch

Eriksson

. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side effects during ten cycles of treatment. Eur. Neuropsychopharmacol. 7, 1624–1632 (1997).

112.

Koren

Nordeng

. Antidepressant use during pregnancy: the benefit-risk ratio. Am. J. Obstet. Gynecol. 207(3) 157–163 (2012).

113.

Andrade

McPhillips

Loren

Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf. 18(3), 246–252 (2009).

114.

Wilson

Zelig

Harvey

Cunningham

Dolinsky

Napolitano

. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am. J. Perinatol. 28(1), 19–24 (2011).

115.

Alwan

Reefhuis

Rasmussen

Friedman

; National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N. Engl. J. Med. 356(26), 2684–2692 (2007).

116.

Myles

Newall

Ward

Large

. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust. NZ J. Psychiatry doi:10.1177/0004867413492219 (2013) (Epub ahead of print).

117.

Grigoriadis

VonderPorten

Mamisashvili

Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J. Clin. Psychiatry 74(4), e293–e308 (2013).

118.

Byatt

Deligiannidis

Freeman

. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr. Scand. 127(2), 94–114 (2013).

119.

Cohen

Soares

Lyster

Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 24(5), 540–543.

120.

Mazza

Harnic

Catalano

Janiri

Bria

. Duloxetine for premenstrual dysphoric disorder: a pilot study. Expert Opin. Pharmacother. 9(4), 517–521 (2008).

121.

Ramos

Hara

Rocha

. Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial. Int. J. Neuropsychopharmacol. 12(8) 1081–1088 (2009).

122.

Schmidt

Grover

Rubinow

. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 50(6), 467–473 (1987).

123.

Smith

Rinehart

Ruddock

Schiff

. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet. Gynecol. 70(1), 37–43 (1987).

124.

Harrison

Endicott

Nee

. Treatment of premenstrual dysphoria with alprazolam. Arch. Gen. Psychiatry 47(3), 270–275 (1990).

125.

Freeman

Rickels

Sondheimer

Polansky

. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 274(1), 51–57 (1995).

126.

Young

Hurt

Benedek

Howard

. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J. Clin. Psychiatry 59(2), 76–80 (1998).

127.

Rickels

Freeman

Sondheimer

. Buspirone in treatment of premenstrual syndrome. Lancet 1(8641), 777 (1989).

128.

Landen

Eriksson

Sundblad

Andersch

Naessen

Eriksson

. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone, and placebo. Psychopharmacology (Berl.) 155(3), 292–298 (2001).

129.

Bäckström

Hansson-Malmstrom

Lindhe

Cavalli-Bjorkman

Nordenstrom

. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 46(3), 253–268 (1992).

130.

Bancroft

Rennie

. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J. Psychosom. Res. 37(2), 195–202.

131.

Graham

Sherwin

. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J. Psychosom. Res. 36(3), 257–266 (1992).

132.

Joffe

Cohen

Harlow

. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am. J. Obstet. Gynecol. 189(6), 1523–1530 (2003).

133.

Sulak

Scow

Preece

Riggs

Kuehl

. Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol. 95(2), 261–266 (2000).

134.

Sulak

Kuehl

Ortiz

Shull

. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am. J. Obstet. Gynecol. 186(6), 1142–1149 (2002).

135.

Halbreich

Freeman

Rapkin

Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception 85(1), 19–27 (2012).

136.

Freeman

Halbreich

Grubb

An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 85(5), 437–445 (2012).

137.

Yonkers

Brown

Pearlstein

Foegh

Sampson-Landers

Rapkin

. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol. 106(3), 492–501 (2005).

138.

Relevant study of oral contraceptive pill treatment of premenstrual dysphoric disorder.

139.

Pearlstein

Bachmann

Zacur

Yonkers

. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72(6), 414–421 (2005).

140.

Lopez

Kaptein

Helmerhorst

. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2, CD006586 (2008).

141.

Joffe

Petrillo

Viguera

Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J. Clin. Psychiatry 68(12), 1954–1962 (2007).

142.

Wang

Hammarback

Lindhe

Bäckström

. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet. Gynecol. Scand. 74(10), 803–808 (1995).

143.

Burnet

Radden

Easterbrook

McKinnon

. Premenstrual syndrome and spironolactone. Aust. N. Z. J. Obstet. Gynaecol. 31(4), 366–368 (1991).

144.

Muhn

Krattenmacher

Beier

Elger

Schillinger

. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 51(2), 99–110 (1995).

145.

Dinger

Heinemann

Kuhl-Habich

. The safety of a drosperinone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75(5), 344–354 (2007).

146.

Manzoli

De Vito

Marzuillo

Voccia

Villari

. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf. 35(3), 191–205 (2012).

147.

Dinger

Shapiro

. Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. J. Fam. Plann. Reprod. Health Care 38(1), 2–6 (2012).

148.

Excellent discussion of safety of drosperinone-containing oral contraceptives.

149.

Smith

Studd

Zamblera

Holland

. A randomized comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br. J. Obstet. Gynaecol. 102(6), 475–484 (1995).

150.

Scarabin

Oger

Plu-Bureau

. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362(9382), 428–432 (2003).

151.

Watts

Butt

Edwards

Logan R

. A clinical trial using danazol for the treatment of premenstrual tension. Br. J. Obstet. Gynaecol. 94(1), 30–34 (1987).

152.

O'Brien

Abukhalil

. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danzol. Am. J. Obstet. Gynecol. 180(1 Pt 1), 18–23 (1999).

153.

Oksa

Luukkaala

Maenpaa

. Toremifene for premenstrual mastalgia: a randomized, placebo-controlled crossover study. BJOG 113(6), 713–718 (2006).

154.

Leather

Studd

Watson

Holland

. The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo-controlled study. Gyencol. Endocrinol. 13(1), 48–55 (1999).

155.

Freeman

Sondheimer

Rickels

. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacology 33(2), 303–309 (1997).

156.

Brown

Ling

Andersen

Farmer

Arheart

. Efficacy of depot leuoprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet. Gynecol. 84(5), 779–786 (1994).

157.

Mortola

Girton

Fischer

. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J. Clin. Endocrinol. Metab. 72(2), 252A–252F (1991).

158.

Di Carlo Palomba

Tommaselli

Guida

Di Spiezio Sardo

Nappi

. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil. Steril. 75(2), 380–384 (2001).

159.

Mitwally

Gotleib

Casper

. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 9(4), 236–241 (2002).

160.

Parker

Feskanich

Broder

Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet. Gynecol. 121(4), 709–716 (2013).

161.

Girman

Lee

Kligler

. An integrative approach to premenstrual syndrome. Am. J. Obstet. Gynecol. 188(5 Suppl.), S56–S65 (2003).

162.

Rossignol

Bonnlander

. Caffeine-containing beverages, total fluid consumption, and premenstrual syndrome. Am. J. Public Health 80(9), 1106–1110 (1990).

163.

Sayegh

Schiff

Wurtman

Spiers

McDermott

Wurtman

. The effect of carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet. Gynecol. 86(4 Pt 1), 520–528 (1995).

164.

Whelan

Jurgens

Naylor

. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can. J. Clin. Pharmacol. 16(3), e407–e429 (2009).

165.

Thys-Jacobs

Starkey

Bernstein

Tian

. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am. J. Obstet. Gynecol. 179(2), 444–452 (1998).

166.

Ghanbari

Haghollahi

Shariat

Roroshani

Ashrafi

. Effects of calcium supplement therapy in women with premenstrual syndrome. Taiwan. J. Obstet. Gynecol. 48(2), 124–129 (2009).

167.

Wyatt

Dimmock

Jones

O'Brien

Shaughn PM

. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 318(7195), 1375–1381 (1999).

168.

Schellenberg

. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled trial. BMJ 322(7279), 134–137 (2001).

169.

Atmaca

Kumru

Tezcan

. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum. Psychopharmacol. 18(3), 191–195 (2003).

170.

Stevinson

Ernst

. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. BJOG 107(7), 870–876 (2000).

171.

Dante

Faccinetti

. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J. Psychosom. Obstet. Gynaecol. 32(1), 42–51 (2011).

172.

Henderson

Yue

Bergquist

Gerden

Arlett

. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br. J. Clin. Pharmacol. 54(4), 3489–3456 (2002).

173.

Hall

Wang

Huang

The interaction between St John's wort and an oral contraceptive. Clin. Pharmacol. Ther. 74(6), 525–535 (2003).

174.

Hunter

Ussher

Browne

Cariss

Jelley

Katz

. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J. Psychosom. Obstet. Gynaecol. 23(2), 193–199 (2002).

175.

Busse

Montori

Krasnik

Patellis-Siotis

Guyatt

. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother. Psychosom. 78(1), 6–15 (2009).

176.

Lustyk

Gerrish

Shaver

Keys

. Cognitive–behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch. Womens Ment. Health 12(2), 85–96 (2009).

177.

Steege

Blumental

. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J. Psychosom. Res. 37(2), 127–133 (1993).

178.

Daley

. Exercise and premenstrual symptomatology: a comprehensive review. J. Womens Health (Larchmt.) 18(6), 895–899 (2009).

179.

Schechter

Boivin

. Sleep, hormones, and circadian rhythms throughout the menstrual cycle in healthy women and women with premenstrual dysphoric disorder. Int. J. Endocrinol. 2010, 259345 (2010).

180.

Parry

Mostofi

Leveau

Sleep EEG studies during early and late partial sleep deprivation in premenstrual dysphoric disorder and normal control subjects. Psychiatry Res. 85(2), 128–143 (1999).

181.

Parry

Meliska

Martinez

Late, but not early, wake therapy reduces morning plasma melatonin: relationship to mood in premenstrual dysphoric disorder. Psychiatry Res. 161, 76–86 (2008).

182.

Parry

Mahan

Mostofi

Klauber

Lew

Gillin

. Light therapy of late luteal phase dysphoric disorder: an extended study. Am. J. Psychiatry 146(9), 1215–1217 (1989).

183.

Lam

Carter

Misri

Kuan

Yatham

Zis

. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res. 86(3), 185–192 (1999).

184.

Krasnik

Montori

Guyatt

Heels-Ansdell

Busse

. The effect of bright light therapy on depression associated with premenstrual dysphoric disorder. Am. J. Obstet. Gynecol. 193(3 Pt 1), 658–661 (2005).

185.

Pincus

Alam

Rubinow

Bhuvaneswar

Schmidt

. Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics. J. Psychiatr. Res. 45(3), 386–394 (2011).

186.

Halbriech

. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr. 13(7), 566–572 (2008).

187.

Westberg

Eriksson

. Sex steroid-related candidate genes in psychiatric disorders. J. Psychiatry Neurosci. 33(4), 319–330 (2008).

188.

Kendler

Karkowski

Core

Neale

. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am. J. Psychiatry 155(9), 1234–1240 (1998).

189.

Derntl

Kryspin-Exner

Fernback

Moser

Habel

. Emotion recognition accuracy in healthy young females is associated with cycle phase. Horm. Behav. 53(1), 90–95(2008).

190.

Protopopescu

Pan

Altemus

Orbitofrontal cortex activity related to emotional processing changes across the menstrual cycle. Proc. Natl Acad. Sci. USA 102(44), 16060–16065 (2005).

191.

MRI study of the effect of the menstrual cycle on emotional processing.

192.

Bartova

Berger

Pezawas

. Is there a personalized medicine for mood disorders? Eur. Arch. Psychiatry Clin. Neurosci. 260(Suppl. 2), S121–S126 (2010).

193.

Scharinger

Rabl

Sitte

Pezawas

. Imaging genetics of mood disorders. Neuroimage 53(3), 810–821 (2010).

194.

Klatzkin

Lindgren

Forneris

Girdler

. Histories of major depression and premenstrual dysphoric disorder: evidence for phenotypic differences. Biol. Psychol. 84(2), 235–247 (2010).

195.

Dhingra

Magnay

O'Brien

Chapman

Fryer

Ismail

. Serotonin receptor 1A C (-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstet. Gynecol. 110(4), 788–792 (2007).

196.

Damberg

Westberg

Berggard

Investigation of transcription factor AP-2 beta genotype in women with premenstrual dysphoric disorder. Neurosci. Lett. 377(1), 49–52 (2005).

197.

Stone

Pearlstein

Brown

. Fluoxetine in the treatment of late luteal dysphoric disorder. J. Clin. Psychiatry 52(7), 290–293 (1991).

198.

Wood

Mortola

Chan

Moossazadeh

Yen

. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet. Gynecol. 80(3), 339–344 (1992).

199.

Menkes

Taghavi

Mason

Spears

Howard

. Fluoxetine treatment of severe premenstrual syndrome. BMJ 305(6849), 346–347 (1992).

200.

Ozeren

Corakci

Yucesoy

Mercan

Erhan

. Fluoxetine in the treatment of premenstrual syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 73(2), 167–170 (1997).

201.

Schmidt

Danaceau

Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 16(5), 346–356 (1997).

202.

Cohen

Miner

Brown

Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet. Gynecol. 100(3), 435–444 (2002).

203.

Freeman

Rickels

Sondheimer

Polansky

. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch. Gen. Psychiatry 56(10), 932–939 (1999).

204.

Pearlstein

Bellew

Endicott

Steiner

. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial. Prim. Care Companion J. Clin. Psychiatry 7(2), 53–60 (2005).

205.

Cohen

Soares

Yonkers

Bellew

Bridges

Steiner

. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom. Med. 66(5), 707–713 (2004).

206.

Miner

Brown

McCray

Gonzales

Wohlreich

. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind placebo-controlled trial. Clin. Ther. 24(2), 417–433 (2002).

207.

Halbreich

Smoller

. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J. Clin. Psychiatry 58(9), 399–402 (1997).

208.

Jermain

Preece

Sykes

Kuehl

Sulak

. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch. Fam. Med. 8(4), 328–332 (1999).

209.

Eriksson

Hedberg

Andersch

Sundblad

. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neurospyschoparhamcology 12(2), 167–176 (1995).

210.

Steiner

Hirschberg

Bergeron

Holland

Gee

Van Erp

. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am. J. Obstet. Gynecol. 193(2), 352–360 (2005).

211.

US FDA. FDA Drug Safety Communication: safety review update on the possible increased risk of blood clots with birth control pills containing drospirenone (2011). www.fda.gov/Drugs/DrugSafety/ucm273021.htm